Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsing multiple sclerosis (RMS) (McDonald Criteria 2010)
Active disease
Expanded disability status scale (EDSS) 0 - 5.5 (inclusive) at screening
You may not be if
Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment
Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and Stem cell transplantation
Diagnosed with primary progressive multiple sclerosis (PPMS)
Pregnant or nursing
Clareo Health | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
